{"name":"Zambon SpA","slug":"zambon-spa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1996-01-01","label":"Monurol first approved","drug":"Monurol","drugSlug":"fosfomycin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Monurol","genericName":"FOSFOMYCIN","slug":"fosfomycin","indication":"Enterococcus Urinary Tract Infection","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Safinamide Methanesulfonate","genericName":"Safinamide Methanesulfonate","slug":"safinamide-methanesulfonate","indication":"Parkinson's disease as adjunctive therapy to levodopa in patients with motor fluctuations","status":"marketed"}]}],"pipeline":[{"name":"Monurol","genericName":"FOSFOMYCIN","slug":"fosfomycin","phase":"marketed","mechanism":"Small molecule","indications":["Enterococcus Urinary Tract Infection","Escherichia coli urinary tract infection","Urinary tract infectious disease"],"catalyst":""},{"name":"Safinamide Methanesulfonate","genericName":"Safinamide Methanesulfonate","slug":"safinamide-methanesulfonate","phase":"marketed","mechanism":"Safinamide is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain by blocking the enzyme responsible for dopamine breakdown.","indications":["Parkinson's disease as adjunctive therapy to levodopa in patients with motor fluctuations"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNZEEyUGZRWlUtSlN6VXdkU1JSM3VEM0xYR296UjdXNjJxbzQxaV93NlZXWFdFeVktcC1oOURQMkszQ3c3RlVTbTRkUGI1S2J2VWQ0ckZTcnFBNDVZUzNZMGVxb2dqcnAyT3c1X01oQzg4WkVxQm5nUFA3M3A0OUdnV0dkNGtjU0E?oc=5","date":"2026-02-19","type":"trial","source":"Market Data Forecast","summary":"Europe N-Acetylcysteine Market Size, Share and Trends, 2034 - Market Data Forecast","headline":"Europe N-Acetylcysteine Market Size, Share and Trends, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQZUVmXzFyd1JWckFYTkNEbURfMlIzdXpsYmQtSVBSczVraVJ4Qjc5S3hlZXpyTXd3MU1pYjIxUDN6ZkRITTlEVHREajBaUDR3TDZuMVJQdVZtZU83X3ZDbDdzTW5mTzZ0SlYyVHA1TkpMcEIzaVVmV2hVM3VHcm5GeVNTM3VKaXBDd1RWdmxvMFFSdWVMXzZhZ1FhS1RiQmsyMHdJZWxJYmR3bXExa0hkWi0yUVJKUlAyWUV0b2RhbjYwamJDcEs0?oc=5","date":"2026-01-12","type":"pipeline","source":"pearceip.law","summary":"Open Sesame - the Federal Court Opens the Door to Preliminary Discovery in the Xadago® Dispute - pearceip.law","headline":"Open Sesame - the Federal Court Opens the Door to Preliminary Discovery in the Xadago® Dispute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQR2hMczZSNm9ka1BJdWgtbEQxSlh4MS1oNUt1Z0tvdEVWT0FMalk4Y25OQjJEb1hKUFRuUHRZblB1ZzdJSUMtZHhZMTBQTVVtNS1uSzdyUVh3SU4zOS1JMEZfcnFVTm5oY1c2WGRfaXdYSGZXRTgtdmRieWhtMWlOeFNMOFN3WFFyUGNQLUhEcXh4a0JtZVlKLTFoVUxtNjVubmRZVkEwcnh3MHVyM0d4Z3lBRER3Yy1tZGIzaFdkbGV1VE5MS0Z1NmhFNW8xSWNnUzdSekUwUjdfWkZMTUc3UkxOVWlhaktYeFVkVFlsemJqeDFUbU05c0hzLTRTODN1dzdQanpRSmpSazNOZHdWMzZB?oc=5","date":"2025-08-25","type":"pipeline","source":"globenewswire.com","summary":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight - globenewswire.com","headline":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5TbmkzZ05Pd0lKVmRqZlNtaWlYdTF6WU9kRWFVcVR6aEtqeTlYMFpWeG01ZVotTjVOWThKQTRPaGlkMTg4Qk4tWXpjV2ZNczA3MWEtM3JSQzNEdnZuRG9Ia3RqVEpPOFJSX1dzQ3lUbl9sdU1CWjdsWDhn?oc=5","date":"2025-04-29","type":"regulatory","source":"CHEManager","summary":"Newron Pharmaceuticals SpA - CHEManager","headline":"Newron Pharmaceuticals SpA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxQbHVQVGNLNTFfUHhJR0dZZUxacTk5eVI1TnpHX0p1cnVCOVJzWGVweWs1MDFaNXk1dUZpTXlHNGV1emppS3RXa3llSno2eTlxTUhITDYyQkV3dEtQallScldQZ25aNm9BN1ctc25zeWpSMG5ITE5MenY1U0E2Z1BqWGdTZVF5SFZCYkZIQzRUQVctZkt4cGtRTGF6U1BCbE1ra0pjZ2tFQ2JtTEtDdkpQVVdQNW8yY2xadmVrazBydmtWdFBHaUFrWXVNWDVlMXV0YkNQbGlJdFVLRWI0Sk1haHhlelB5dkNCRkFWRmdlZE9RNEtzMzBCUXhFank5TG92R3hnT3ZkU0pYeUk3S0V1a3RvVDRJNmR1YnE5X2p0b181V3ljNkFJamdlV3FjX1I5X1JyT0pxU2c?oc=5","date":"2024-11-13","type":"pipeline","source":"globenewswire.com","summary":"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over - globenewswire.com","headline":"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-02-29","type":"pipeline","source":"globenewswire.com","summary":"Bronchiolitis Obliterans Syndrome Market to Grow - globenewswire.com","headline":"Bronchiolitis Obliterans Syndrome Market to Grow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AJBVV95cUxQZEdvTWVJRXVDNWo4LWNPSXhLWi1BUXlCc2oxRFFTWE1tamVmT2NDSFFVVG5vLUtrYXZEX2hqRElDeHdjcjgwbmVIR09QYzMwUURZWldVR1ZkaFFaaVJYSVVvbHdXenZZT1QwcnE0SWlZTW5PRnByeDZwYURBd1RRVUN1dVBqN21KRGFtNS1JdzQ2dU5RT1F1TEtPcUpZOTZ3YW1lVHJaeTRGZ2FmdnFJS3BuXy12V1JSSHZrLUZ6NnphOWdod3IwUnhGQXNVUTNPbkE4VXhBOGhFWm9xcnFaeUd4SXlvZm1oTjhHY0duOWhoTGN4Ri1oSXgzbGpWUmJmcmtRczBBZmVBZHl6aGFHU3FTMnRIREwtX3lVVEVKMHRkRTkzUHY1WW5wNHMyb19hWmswMWVSams3dEdYNXk0Skx3NjR0QlduLVpsUTU5cU5QUmgxODZ5aw?oc=5","date":"2023-05-01","type":"trial","source":"PR Newswire","summary":"Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS) - PR Newswire","headline":"Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOSXViNUNhUERZcWpOTm80M3l1ZDR6R1NXRVM4RmMwdDZIU3NsRTJ3UHgwMWw4ejE3RngxbXFza3VtSThGUVZLZHM3Q3pSMlRjY1VzSk13WkdPTWZsa0t0RkVrNzNudUhjTm9OS0tqYmVWZ2ZvY2ZzSmJSZ3V3TmZmcVFVRm0yS0FxODQzdkpnX0lrR3c3djAzRXNUNnBWVHpFVXVPS0xKck85b0w2LXNEVkFmZ2RPNlpSdFo2Vk85RUhyVlF2bTFMUEo4UlRZN1JlbGpxWlN5bnRvbFBIaXIydGNhOGN2ZVE?oc=5","date":"2022-04-21","type":"regulatory","source":"BioSpace","summary":"Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) - BioSpace","headline":"Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQaDdva09aQ2k4MXZjOG5jS2Nwc0F3QzBQRDNnb21QallfQ21hUVdqR1ZMNW1JZjU3SldiRmQ4bUpIblhKMVNxMlVad1htYXoycks2VWNCU1lMVlczQ2RKWHNORFRrT1ZnZmNWSDFLdjY4d0JfVkVaRmgtbzJBa1VXa21vTEQxTExWTWx3bWYyaHpldEtuTGQxczJlM2FabVZhT3Z5RnJhOERfMlowTlRCd19LMVRRanpDZ1lNVU1QOU05d1pLeXJHMFlGbWIwOGRUVUpOQ0xWNThxS2VMYlZuOW1MNV9VUkRFWVplMFYzOHFQeW5PUlNHQ19nV3lNUkFxOGVJa2xPalN1N3BRMHMydF9aQlZkdHFBN3JkbG1Cb1c4YVloa19PVHZCSGhlM2dLNFRQY1I2OA?oc=5","date":"2022-03-15","type":"earnings","source":"Global Design News","summary":"Michele De Lucchi’s design for a new headquarters for a pharmaceutical corporation outside Milan promotes new ways of living the office space in line with the Studio’s research philosophy - Global Des","headline":"Michele De Lucchi’s design for a new headquarters for a pharmaceutical corporation outside Milan promotes new ways of li","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxONXRaZVN2MTVKbUNINlV3ZWg3SkJtWUlnTFR4aFlBYTR3V0tPS054THk1RGVnU05JaGF6SDFpN1VpdUVwQnJEZlZ1Y0JoTlRlZmNJa3c2T1RzLUVDSkZmdUx5ZGl5OWREbGJod2xsMFVRcGYwT2NuMDl5X1IyZ202LWxQdWhkeHdpUkMtcy1lQ21WTEY0ZEFkYm9YU3Q0YTdkTldiT0NYdXFSaGhmOFJKSFUydEkwNUV5VTc3QkV2OHlwYnYwUVRKQWMzMWhHZVdMeVJ6V1pBMnRRbHFrUGhscUpkV1VnNjFYUzBHUDNvV3dLdFdJUFA3U2Q3Zlo?oc=5","date":"2019-07-10","type":"pipeline","source":"Newswire Canada","summary":"Valeo Pharma Announces the Canadian Launch of Onstryv® (Safinamide Tablets) for the Treatment of Parkinson's Disease - Newswire Canada","headline":"Valeo Pharma Announces the Canadian Launch of Onstryv® (Safinamide Tablets) for the Treatment of Parkinson's Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPSTlXTkt1Q3lyei0tMGQxb3E5bGpEZFJrX2xSUWEyOGZJZlZaV2t6NHJ3b2p5RmIzdXZEWG5DQnBXXzFhWEFzbDh4cDI0T1RKNndHUXlHd25fTG1ndUhmd19uT0pFMENVNUkyWm50eFVfMEJoQ0ZaSXlYYTdsVnVjaWZjUVZmSU1vQ21EMmx0aFd1NGZNVmdCaUtmUEQyZWpmMkE?oc=5","date":"2015-07-14","type":"pipeline","source":"PR Newswire UK","summary":"Zambon Expands in Europe Acquiring Nigaard - PR Newswire UK","headline":"Zambon Expands in Europe Acquiring Nigaard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPNGpYUF9FMkxqTzFneVVFSG5VSWpLR0s1a2NVNzlEWVdKcmlUalFySmlmVmdlT3A0MldselRMMmF4QjBmWV9DSlVUY1A2Yjc2Q1FDUFczR2g3bmJ6bGVWc1NKUXM1VWNFMUVsd3JPalhoUjVCYU5YRTVmMGxKQlhQUURFaEFmR3M?oc=5","date":"2015-05-18","type":"pipeline","source":"Parkinson's News Today","summary":"Xadago To Be Launched in Germany for Parkinson’s Disease - Parkinson's News Today","headline":"Xadago To Be Launched in Germany for Parkinson’s Disease - Parkinson's News Today","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}